Company: Non-Clinical Development Department, Emergent BioSolutions Inc.
Location: Gaithersburg, MD, United States
Janet L. Lathey, Ph.D. is the Director of Immunology and Assay Validation for the Non-Clinical Development Department of Emergent BioSolutions Inc., a global biopharmaceutical company and leading provider of vaccines and therapeutics. With a vast background in immunology, clinical and potency assay qualification and validation, Dr. Lathey utilizes her knowledge of enzyme-linked immunosorbent assay (ELISA) and multiple bioassays when overseeing immunology and assay development, validation and performance, and handling enzyme-linked immunosorbent assays, as well as enzyme-linked immunosorbent spots (ELISpot) assays and toxin neutralization assays. Previously, Dr. Lathey was associate deputy director for global clinical immunology at Sanofi Pasteur in Swiftwater, Pa. As a project representative, she was involved with standardizing assays for influenza clinical trials and efficacy studies. Before moving to Sanofi Pasteur, Dr. Lathey was director of virology and immunology at SeraCare in Gaithersburg, Md. In this capacity, she was responsible for developing an ELIspot kit for market and setting up proficiency testing using ELIspot for HIV and cancer programs. Previous to SeraCare she was a clinical immunology group leader at ZYCOS in Lexington, Mass. There she was involved in testing a therapeutic vaccine for human papillomavirus (HPV), a sexually transmitted disease. Before moving into industry, Dr. Lathey was co-director of the Retrovirology Laboratory at the University of California, San Diego, where she was involved in the immunological and virological evaluations of anti-retroviral clinical trials for the treatment of HIV.
Contact Janet L. Lathey, Ph.D.